<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01410201</url>
  </required_header>
  <id_info>
    <org_study_id>OZURDEX ERM</org_study_id>
    <nct_id>NCT01410201</nct_id>
  </id_info>
  <brief_title>Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane</brief_title>
  <acronym>OZURDEX2</acronym>
  <official_title>Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barnes Retina Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barnes Retina Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of dexamethasone intravitreal implant
      (Ozurdex) in combination with pars plana vitrectomy and membrane peeling for idiopathic
      epiretinal membrane (ERM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pars plana vitrectomy with membrane peeling has been used for years to successfully to treat
      ERM (epiretinal membrane). However, despite successful surgery, approximately 10-30% of
      patients may not experience any improvement in visual acuity (ref. 1-7). Macular causes of
      unsatisfactory visual outcome following vitrectomy include persistent macular edema and
      reoccurrence of epiretinal membrane (ref. 1-7). Concomitant administration of intravitreal
      corticosteroids (triamcinolone acetonide) after pars plana vitrectomy and membrane peeling
      for epiretinal membrane has been reported to speed up and improve the anatomic and functional
      outcome (ref 8). Given that intravitreal triamcinolone has been reported to last
      approximately 113 days ina post-vitrectomy eye (ref. 9); the investigators postulate that a
      longer-acting corticosteroid such as Ozurdex could not only have the benefits of improved
      anatomic and functional outcomes, but also a longer sustained effect.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment not met
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>At all study visits:
ETDRS visual acuity will be measured visit excluding post op day 1 (snellen visual acuity will be measured).
Intraocular pressure (IOP) will be checked. Spectral Domain Optical Coherence Tomography (OCT). Dilated fundus exam.
At Pre Op, Post Op Week 4, 8, 12, 16, 20 and 24 visits:
ETDRS visual acuity will be measured. IOP check. Spectral Domain OCT. Fundus photography. Fundus Autofluorescence (AF). Fluorescein Angiography (FA). Dilated Fundus exam.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of persistent macular edema on Central OCT thickness in treatment (PPV + MP + DEX) versus non-treatment (PPV + MP) groups</measure>
    <time_frame>6 months</time_frame>
    <description>At all visits: ETDRS visual acuity will be measured except post op day 1 (snellen visual acuity will be measured) Intraocular pressure (IOP) will be checked Spectral Domain Optical Coherence Tomography (OCT) Dilated fundus exam
At Pre Op, Post Op Week 4, 8, 12, 16, 20, and 24:
ETDRS visual acuity will be measured IOP will be checked Spectral Domain OCT Fundus Photography Fundus Auto Fluorescence (AF) Fluorescein Angiography (FA) Dilated Fundus exam</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Epiretinal Membrane</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>PPV + MP + DEX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV + MP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Intravitreal Implant</intervention_name>
    <description>Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.</description>
    <arm_group_label>PPV + MP + DEX</arm_group_label>
    <arm_group_label>PPV + MP</arm_group_label>
    <other_name>Pars Plana Vitrectomy</other_name>
    <other_name>Membrane Peel</other_name>
    <other_name>Dexamethasone Intravitreal Implant (Ozurdex)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with idiopathic epiretinal membrane

          -  Preoperative visual acuity of snellen equivalent 20/32 or worse

        Exclusion Criteria:

          -  History or presence of any of the following:

          -  uveitis

          -  macular hole

          -  previous vitreoretinal surgery

          -  any other retinal pathology that could affect anatomic or functional results

          -  Age Related Macular Degeneration

          -  Diabetic Retinopathy

          -  Diabetic Macular Edema

          -  Retinal Vein Occlusion

          -  Pre-existing Macular Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaurav K Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Lukes Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Eye Surgery and Laser Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smiddy WE, Michels RG, Green WR. Morphology, pathology, and surgery of idiopathic vitreoretinal macular disorders. A review. Retina. 1990;10(4):288-96. Review.</citation>
    <PMID>2089546</PMID>
  </reference>
  <reference>
    <citation>de Bustros S, Thompson JT, Michels RG, Rice TA, Glaser BM. Vitrectomy for idiopathic epiretinal membranes causing macular pucker. Br J Ophthalmol. 1988 Sep;72(9):692-5.</citation>
    <PMID>3179258</PMID>
  </reference>
  <reference>
    <citation>Michels RG. Vitrectomy for macular pucker. Ophthalmology. 1984 Nov;91(11):1384-8.</citation>
    <PMID>6514308</PMID>
  </reference>
  <reference>
    <citation>McDonald HR, Verre WP, Aaberg TM. Surgical management of idiopathic epiretinal membranes. Ophthalmology. 1986 Jul;93(7):978-83.</citation>
    <PMID>3763143</PMID>
  </reference>
  <reference>
    <citation>Schadlu R, Tehrani S, Shah GK, Prasad AG. Long-term follow-up results of ilm peeling during vitrectomy surgery for premacular fibrosis. Retina. 2008 Jun;28(6):853-7. doi: 10.1097/IAE.0b013e3181631962.</citation>
    <PMID>18536602</PMID>
  </reference>
  <reference>
    <citation>Koerner F, Garweg J. Vitrectomy for macular pucker and vitreomacular traction syndrome. Doc Ophthalmol. 1999;97(3-4):449-58.</citation>
    <PMID>10896363</PMID>
  </reference>
  <reference>
    <citation>Massin P, Allouch C, Haouchine B, Metge F, Paques M, Tangui L, Erginay A, Gaudric A. Optical coherence tomography of idiopathic macular epiretinal membranes before and after surgery. Am J Ophthalmol. 2000 Dec;130(6):732-9.</citation>
    <PMID>11124291</PMID>
  </reference>
  <reference>
    <citation>Konstantinidis L, Berguiga M, Beknazar E, Wolfensberger TJ. Anatomic and functional outcome after 23-gauge vitrectomy, peeling, and intravitreal triamcinolone for idiopathic macular epiretinal membrane. Retina. 2009 Sep;29(8):1119-27. doi: 10.1097/IAE.0b013e3181ac23da.</citation>
    <PMID>19734764</PMID>
  </reference>
  <reference>
    <citation>Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye. Br J Ophthalmol. 2006 Jun;90(6):705-8. Epub 2006 Mar 10.</citation>
    <PMID>16531422</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>August 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2011</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barnes Retina Institute</investigator_affiliation>
    <investigator_full_name>Rhonda Weeks</investigator_full_name>
    <investigator_title>Gaurav K. Shah, MD</investigator_title>
  </responsible_party>
  <keyword>Epiretinal Membrane</keyword>
  <keyword>Macular Edema</keyword>
  <keyword>Dexamethasone Intravitreal Implant (Ozurdex)</keyword>
  <keyword>Pars Plana Vitrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Temazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

